A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: An exploratory study

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 6, 2006, Pages 687-698

  Markowitz, John S ^a   DeVane, C Lindsay ^b   Pestreich, Linda K ^c   Patrick, Kennerly S ^a   Muniz, Rafael ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Norvartis Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; ATROPINE; DESIPRAMINE; DEXMETHYLPHENIDATE; IMIPRAMINE; METHYLPHENIDATE; NORADRENALIN TRANSPORTER; SEROTONIN 1A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL CELL; ARTICLE; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BINDING SITE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; ENANTIOMER; EXPLORATORY RESEARCH; ISOMERISM; LOCOMOTION; MOLECULAR INTERACTION; MOOD; NEUROTRANSMISSION; NONHUMAN; QUANTITATIVE ANALYSIS; RACEMIC MIXTURE; SEROTONINERGIC TRANSMISSION;

EID: 33846584513     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.687     Document Type: Article

References (52)

1. Arnsten AF, Dudley AG: Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoreceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Func 1:1-9, 2005.
2. Baldessarini R, Cambell A: Method of dopamine inhibition using l-threo-methylphenidate. US patent 6,221,883, 2001.
3. Barkley RA, Fischer M, Smallish L, Fletcher K: The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of a reporting source and definition of the disorder. J Abnorm Psychol 111:279-289, 2002.
4. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152, 1999.
5. Barr CL, Wigg KG, Feng Y, et al.: Attention-deficit hyperactivity disorder and the gene for the dopamine D5 receptor. Mol Psychiatry 5:548-551, 2001.
6. Biederman J: Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 57:1215-1220, 2005.
7. Biederman J, Spencer T: Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242, 1999.
8. Biederman J, Spencer T, Wilens T: Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 7:77-97, 2004.
9. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711, 2002.
10. Cheng Y, Prusoff, WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 23:3099-108, 1973.
11. Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Blake H, Dietz G, Saucier G, MacMurray JP: Comparison of the role of dopamine, serotonin, and noradrenaline genes in ADHD, ODD and conduct disorder: multivariate regression analysis of 20 genes. Clin Genet 57:178-196, 2000.
12. Davids E, Zhang K, Tarazi FI, Baldessarini RJ: Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology 160:92-98, 2002a.
13. Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ: Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther 301:1097-1102, 2002b.
14. Ding Y-S, Fowler JS, Volkow ND: Is the 1-threo enantiomer of methylphenidate (Ritalin) inactive in the brain when given orally. Am Col Neuropsychopharmacol, San Juan, December 8-12: 255, 2002 (abstract).
15. Ding YS, Gatley SJ, Thanos PK, et al.: Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse 53:168-175, 2004.
16. Entzeroth M, Chapelain B, Guilbert J, Hamon V: High throughput drug profiling. J Automat Meth Management Chem 22:171-173, 2000.
17. Faraone SV, Sergeant J, Gillberg C, Biederman J: The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry 2:104-113, 2003.
18. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P: Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1313-1323, 2005.
19. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG: Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity (attention-deficit hyperactivity disorder and psychostimulants). Science 283:397-401, 1999.
20. Homer CJ, Baltz RD, Hickson GB, et al.: Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105:1158-1170, 2000.
21. Huang Y-Y, Battistuzzi C, Oquendo MA, Harkavy-Friedman J, Greenhill L, Zalsman G, Brodsky B, Arango V, Brent DA, Mann JJ: Human 5-HT1S receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol 7:441-451, 2004.
22. Keating GM, Figgitt DP: Dexmethylphenidate. Drugs 62:1899-1904, 2002.
23. 1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 313:25-34, 1996.
24. Kleven MS, Koek W: Discriminative stimulus properties of cocaine: Enhancement by monoamine reuptake blockers. J Pharmacol Exp Ther 284:1015-1025, 1998.
25. Krause K-H, Dresel SH, Krause J, la Fougere C, Ackenheil M: The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 27:605-613, 2003.
26. Kuczenski R, Segal DS: Effects of methylphenidate on extracellular dopamine serotonin and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037, 1997.
27. Kuczenski R, Segal DS: Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: Relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296:876-883, 2001.
28. Leonard BE, McCartan D, White J, King DJ: Methylphenidate: A review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol Clin Exp 19:151-180, 2004.
29. Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1397-1409, 2005.
30. Markowitz, JS, Straughn AB, Patrick, KS: Advances in the pharmacotherapy of attention-deficit hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 23:1281-1299, 2003.
31. Mihda KK, Teicher M, Kumar V: Method of treating depression using 1-threo-methylphenidate. US patent 6,395,752, 2002.
32. Modi NB, Wang B, Noveck RJ, et al.: Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic controlled-release oral delivery system. J Clin Pharmacol 40:1141-1149, 2000.
33. Naughton M, Mulrooney JB, Leonard BE: A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 6:397-415, 2000.
34. Pan D, Gatley SJ, Dewey SL, Chen R, Alexoff DA, Ding Y-S, Fowler JS: Binding of bromine-substituted analogs of methylphenidate to monoamine transporters. Eur J Pharmacol 264:177-182, 1994.
35. Patrick KS, Kilts CD, Breese GR: Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 29:1237-1240, 1981.
36. Patrick KS, Caldwell RW, Ferris RM, et al.: Pharmacology of the enantiomers of threo methylphenidate. J Pharmacol Exp Ther 241:152-158, 1987.
37. Patrick KS, Gonzalez MA, Straughn AB, Markowitz JS: New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Delivery 2:121-143, 2005a.
38. Patrick KS, Straughn AB, Yeatts S, Herrin AE, De-Vane CL, Malcolm R, Minhinnett RR, Janis GC, Markowitz JS: Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (in press).
39. Pierce DM, Dixon CM, Wigal SB, McGough JJ: Pharmacokinetics of methylphenidate transdermal system in children with attention-deficit hyperactivity disorder. Poster presented at the Joint Meeting of the American Academy of Child and Adolescent Psychiatry and the Canadian Academy of Child & Adolescent Psychiatrists, October 20th, 2005, Toronto, Ontario, Canada.
40. Pliszka SR: The neuropsychopharmacology of attention-deficit/ hyperactivity disorder. Biol Psychiatry 57:1385-1390, 2005.
41. Quist JF, Kennedy JL: Genetics of childhood disorders: XXIII, ADHD, Part 7: The serotonin system. J Am Acad Child Adoles Psychiatry 40:253-256, 2001.
42. Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, Basile VS, Beitchman J, Kennedy JL: The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder Mol Psychiatry 8:98-102, 2003.
43. 7) using a macrocyclic antibiotic as the chiral selector. Rapid Commun Mass Spectrom 13:2054-2062, 1999.
44. Rothman RB, Bauman MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41, 2001.
45. Rouhi AM: Chirality at work. Chem Eng News May 4:56-61, 2003.
46. Solanto MV: Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: A review and integration. Behav Brain Res 94:127-152, 1998.
47. Srinivas NR, Hubbard JW, McKay G, Hawes EM, Midha KK: In vitro hydrolysis of RR, SS threo-methylphenidate by blood esterases-differential and enantioselective interspeces differences. Chirality 3:99-103, 1991.
48. Srinivas NR, Hubbard JW, Quinn D, et al.: Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 152:561-568, 1992.
49. Srinivas NR, Hubbard JW, Korchinski ED, et al.: Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res 10:14-21, 1993.
50. Teo SK, Stirling DI, Hoberman AM, et al: D-Methylphenidate and D,L-Methylphenidate are not developmental toxicants in rats and rabbits. Birth Def Res (Part B) 68:162-171, 2003.
51. Wall SC, Gu H, Rudnick G: Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: Amphetamine specificity for inhibition and efflux. Mol Pharmacol 47:544-550, 1995.
52. Yang L, Wang Y-F, Li J, Faraone SV: Association of norepinephrine transported gene with methylphenidate response. J Am Acad Child Adoles Psychiatry 43:1154-1158, 2004.